The Insulin Cost Reduction Act
This bill prohibits the negotiation of price concessions between insulin manufacturers and prescription drug plans under the Medicare prescription drug benefit unless the price concessions are either provided at the point of sale to beneficiaries or are reflected in cost-sharing requirements.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.